Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedJul 21, 2026
DataAggregated Company Financials
Companies47
  • 7D-1.4%
  • 3M3.0%
  • 1Y26.2%
  • YTD16.2%

Over the last 7 days, the Biotech industry has dropped 1.4%, driven by a pullback from Bonesupport Holding of 16%. This takes the industry's 12 month performance to a gain of 26%. Looking forward, earnings are forecast to grow by 33% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 21 Jul 2026SEK 244.9bSEK 38.5b-SEK 6,142,972,566.5434.7x-39.9x6.4x
Thu, 18 Jun 2026SEK 238.5bSEK 38.4b-SEK 6,193,457,763.4435.9x-38.5x6.2x
Sat, 16 May 2026SEK 247.8bSEK 39.2b-SEK 5,321,447,952.1428.2x-46.6x6.3x
Mon, 13 Apr 2026SEK 232.3bSEK 38.5b-SEK 5,655,163,322.6917.9x-41.1x6x
Wed, 11 Mar 2026SEK 223.4bSEK 38.5b-SEK 5,719,597,177.0117.7x-39.1x5.8x
Fri, 06 Feb 2026SEK 220.0bSEK 38.2b-SEK 5,994,802,570.5427x-36.7x5.8x
Sun, 04 Jan 2026SEK 205.8bSEK 38.1b-SEK 556,438,823.7533.6x-369.8x5.4x
Tue, 02 Dec 2025SEK 208.6bSEK 38.1b-SEK 568,121,905.5432.6x-367.2x5.5x
Thu, 30 Oct 2025SEK 207.1bSEK 37.3b-SEK 1,169,434,402.4039.2x-177.1x5.5x
Sat, 27 Sep 2025SEK 192.5bSEK 36.4bSEK 3.0b31x63.6x5.3x
Mon, 25 Aug 2025SEK 196.3bSEK 35.9bSEK 2.7b29.2x73.8x5.5x
Wed, 23 Jul 2025SEK 185.1bSEK 35.9bSEK 2.8b28.1x66.2x5.2x
Fri, 20 Jun 2025SEK 179.0bSEK 35.2bSEK 2.2b28.1x80.3x5.1x
Sun, 18 May 2025SEK 192.5bSEK 33.9bSEK 1.2b34.5x160.3x5.7x
Tue, 15 Apr 2025SEK 174.3bSEK 33.7bSEK 750.1m29.2x232.4x5.2x
Thu, 13 Mar 2025SEK 190.3bSEK 33.7bSEK 572.9m32.9x332.2x5.7x
Sat, 08 Feb 2025SEK 220.8bSEK 33.7bSEK 271.4m56.5x813.8x6.6x
Mon, 06 Jan 2025SEK 221.9bSEK 33.0b-SEK 4,422,596,365.77162x-50.2x6.7x
Wed, 04 Dec 2024SEK 210.5bSEK 33.0b-SEK 4,446,083,898.88147x-47.3x6.4x
Fri, 01 Nov 2024SEK 222.9bSEK 33.2b-SEK 4,481,372,282.23140.8x-49.7x6.7x
Sun, 29 Sep 2024SEK 217.6bSEK 31.4b-SEK 5,542,929,538.9352.3x-39.3x6.9x
Tue, 27 Aug 2024SEK 208.5bSEK 31.4b-SEK 5,451,327,747.7949.3x-38.2x6.6x
Thu, 25 Jul 2024SEK 213.3bSEK 31.4b-SEK 5,424,901,690.8146.7x-39.3x6.8x
Sat, 22 Jun 2024SEK 193.1bSEK 30.6b-SEK 5,516,987,376.4139x-35x6.3x
Mon, 20 May 2024SEK 191.4bSEK 30.6b-SEK 5,502,584,440.7639.8x-34.8x6.3x
Wed, 17 Apr 2024SEK 179.8bSEK 29.8b-SEK 5,280,636,096.3364.7x-34.1x6x
Fri, 15 Mar 2024SEK 189.6bSEK 29.8b-SEK 5,636,094,080.7062.7x-33.6x6.4x
Sun, 11 Feb 2024SEK 176.4bSEK 29.6b-SEK 5,721,591,027.0660.4x-30.8x6x
Tue, 09 Jan 2024SEK 186.5bSEK 28.7b-SEK 1,198,163,513.0061.3x-155.6x6.5x
Thu, 07 Dec 2023SEK 174.1bSEK 28.7b-SEK 1,200,279,947.0058.5x-145.1x6.1x
Sat, 04 Nov 2023SEK 159.4bSEK 28.6b-SEK 1,296,096,406.0049x-123x5.6x
Mon, 02 Oct 2023SEK 161.8bSEK 27.4b-SEK 2,016,197,047.0051.3x-80.2x5.9x
Wed, 30 Aug 2023SEK 154.1bSEK 27.6b-SEK 1,820,362,233.0052.9x-84.6x5.6x
Fri, 28 Jul 2023SEK 155.3bSEK 27.5b-SEK 1,530,732,732.0058.6x-101.5x5.6x
Price to Earnings Ratio

-101.5x


Total Market Cap: SEK 155.3bTotal Earnings: -SEK 1,530,732,732.00Total Revenue: SEK 27.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -40x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 12% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market-0.20%
Healthcare-0.079%
Biotech-1.37%
Biotech-1.37%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 465.002.4%
+SEK 3.8b		71.8%PE174.6x
BIOG B BioGaiaSEK 120.402.4%
+SEK 283.3m		22.0%PE35.1x
HAMLET B Hamlet BioPharmaSEK 4.2014.3%
+SEK 93.3m		1.4%PS4191x
VITR VitrolifeSEK 88.650.6%
+SEK 74.5m		-38.0%PS3.5x
HNSA Hansa BiopharmaSEK 33.382.0%
+SEK 65.1m		29.0%PS17.8x

Latest News

DVYSR
SEK 62.40
Devyser Diagnostics
7D
1.3%
1Y
-57.0%
Narrative Update • Jul 20

DVYSR: Italian Tender Wins Will Support Long-Term Genetic Diagnostics Momentum

Analysts have trimmed their price target for Devyser Diagnostics to SEK120.86 from SEK156.12, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that point to a more conservative valuation framework. What's in the News Devyser Diagnostics launched One Lambda Devyser Chimerism Plus, a next generation solution for chimerism analysis following allogeneic hematopoietic stem cell transplantation.
BONEX
SEK 202.00
Bonesupport Holding
7D
-12.7%
1Y
-35.5%
Narrative Update • Jul 20

BONEX: Share Buybacks Will Support Bullish Case Despite Lowered Growth Assumptions

Analysts have reduced their price target for Bonesupport Holding to SEK275 from SEK310, reflecting updated assumptions around a slightly higher discount rate, more moderate revenue growth, a marginally stronger profit margin, and a lower future P/E multiple. What's in the News for Bonesupport Holding Bonesupport Holding AB (publ) plans to commence a share repurchase program on June 9, 2026, following a mandate from the Annual General Meeting on May 12, 2026.
XBRANE
SEK 9.82
Xbrane Biopharma
7D
-8.2%
1Y
-72.8%
BIOG B
SEK 120.40
BioGaia
7D
2.4%
1Y
22.0%
SOBI
SEK 465.00
Swedish Orphan Biovitrum
7D
2.4%
1Y
71.8%
VITR
SEK 88.65
Vitrolife
7D
0.6%
1Y
-38.0%
BIOA B
SEK 307.00
BioArctic
7D
-2.2%
1Y
51.8%
SYNACT
SEK 19.32
SynAct Pharma
7D
-3.9%
1Y
-3.2%
EGTX
SEK 6.35
Egetis Therapeutics
7D
1.9%
1Y
18.0%
Narrative Update • Jul 10

EGTX: Equity Raise And Overweight Rating Will Support Future Upside

Analysts have lifted their fair value estimate for Egetis Therapeutics from SEK 9.78 to SEK 11.90, citing a SEK 23 Street price target and updated assumptions around discount rates, revenue growth and profit margins. What’s in the News for Egetis Therapeutics Egetis Therapeutics AB (publ) has completed a follow on equity offering of approximately SEK 350 million, offering 66,666,667 ordinary shares at SEK 5.25 per share, according to a key developments feed.
VICO
SEK 11.46
Vicore Pharma Holding
7D
-2.6%
1Y
46.7%
SPRINT
SEK 3.59
Sprint Bioscience
7D
-6.5%
1Y
569.8%
HNSA
SEK 33.38
Hansa Biopharma
7D
2.0%
1Y
29.0%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
FLUO
SEK 32.10
FluoGuide
7D
-5.0%
1Y
-22.7%
Narrative Update • Jun 26

FLUO: Strong Brain Tumor Surgery Data Will Support Future Upside

Analysts have revised their price target for FluoGuide to SEK73.85 from SEK123.50, citing updated assumptions on revenue potential, profitability, and a higher future P/E multiple within their valuation work. What’s in the News for FluoGuide FluoGuide presented interim data for its FG001 compound in an investigator-initiated clinical study involving surgery for meningioma and presumed low grade glioma (pLGG).
CURAS
DKK 19.45
Curasight
7D
1.6%
1Y
620.4%
IVACC
SEK 1.14
Intervacc
7D
-10.3%
1Y
9.4%